New Drug Approval for Lasmiditan: A New Approach to

​Migraine Treatment
​
Cassandra Kuhn and Olivia Reiber
Abstract
Millions of people worldwide suffer from migraines, and current treatment may not be suitable for all patients. Patients who have cardiovascular risk factors as well as migraines are not able to take triptans, which are the mainstay of acute migraine treatment, because triptasns can cause an increase in blood pressure and potentially cause an unwanted cardiovascular event. Lasmiditan (Reyvow™) is a newly FDA-approved drug that is indicated for acute treatment of migraine with or without aura in adults that is safe for patients who have cardiovascular risk factors.  This new drug gives hope to many patients who have untreated migraine pain and has the potential to  greatly change the current treatment guidelines for migraines.
Full Text
Lasmiditan_CK_OR.pdf
File Size: 340 kb
File Type: pdf
Download File

Notice and Disclaimer

Medicine is an ever-changing science.  As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required.  The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication.  However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work.    Readers are encouraged to confirm the information contained herein with other sources.   For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.

Subscribe to ARxCH